Eversept Partners, LP Iovance Biotherapeutics, Inc. Transaction History

Eversept Partners, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$27.21 - $41.0 $2.45 Million - $3.69 Million	-90,047 Closed	0 $0
Q1 2020 Nov 08, 2023	BUY	$19.54 - $38.85 $897,022 - $1.78 Million	45,907 Added 104.0%	90,047 $2.7 Million
Q1 2020 May 13, 2020	BUY	$19.54 - $38.85 $1.76 Million - $3.5 Million	90,047 New	90,047 $2.7 Million
Q4 2018 Feb 13, 2019	SELL	$7.51 - $11.93 $331,491 - $526,590	-44,140 Closed	0 $0
Q3 2018 Nov 08, 2023	SELL	$11.25 - $17.7 $122,175 - $192,222	-10,860 Reduced 19.75%	44,140 $496,000
Q3 2018 Nov 14, 2018	SELL	$11.25 - $17.7 $122,175 - $192,222	-10,860 Reduced 19.75%	44,140 $497,000
Q2 2018 Nov 08, 2023	SELL	$12.45 - $16.95 $124,500 - $169,500	-10,000 Reduced 15.38%	55,000 $704,000
Q2 2018 Aug 14, 2018	SELL	$12.45 - $16.95 $124,500 - $169,500	-10,000 Reduced 15.38%	55,000 $704,000
Q1 2018 Nov 08, 2023	BUY	$8.1 - $19.5 $526,500 - $1.27 Million	65,000 New	65,000 $1.1 Billion
Q1 2018 May 14, 2018	BUY	$8.1 - $19.5 $526,500 - $1.27 Million	65,000 New	65,000 $1.1 Million

341

248M

4.04M

3.1M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $879M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.